Myasthenia Gravis: Diagnostic Tests

Recall that myasthenia gravis is associated with skeletal muscle weakness and paralysis due to impaired neuromuscular transmission.

The initial diagnosis of myasthenia gravis is generally made based on the symptoms exhibited and the patient's history.

Edrophonium, a short-acting, reversible cholinesterase inhibitor, is used to diagnose myasthenia because of its short-term effects.

The test starts by injecting two milligrams of edrophonium chloride intravenously. If, within forty-five seconds, no effect is observed, an additional eight milligrams is administered.

Improvement in muscle strength lasting about five minutes is a positive indicator of myasthenia.

Myasthenia-associated muscle weakness can be diagnosed using electromyography and repetitive nerve stimulation, which assesses muscle activity in patients.

As anti-receptor antibodies against the nAChRs are prevalent, detecting their presence in plasma or muscle biopsies can confirm the diagnosis.

Because a thymus gland tumor often accompanies myasthenia, imaging tests can help identify any abnormality of the thymus gland.